UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/595,971	07/02/2007	Stuart Michael Humphrey	80-06	9993	
	7590 02/18/200 INNER AND SULLIV		EXAMINER		
4875 PEARL E SUITE 200	AST CIRCLE	NIEBAUER, RONALD T			
BOULDER, CO	0 80301		ART UNIT	PAPER NUMBER	
			1654		
			MAIL DATE	DELIVERY MODE	
			02/18/2009	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
Office Action Commons	10/595,971	HUMPHREY, STUART MICHAEL				
Office Action Summary	Examiner	Art Unit				
	RONALD T. NIEBAUER	1654				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence ad	ldress			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1)⊠ Responsive to communication(s) filed on 12 Ja	กมลาน 2000					
· <u> </u>	action is non-final.					
		secution as to the	merits is			
	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
siosed in addordance with the practice under E.	parte Quayle, 1000 O.B. 11, 40	0 0.0. 210.				
Disposition of Claims						
4) ☐ Claim(s) 1-15 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 1-15 are subject to restriction and/or e						
Application Papers						
9)☐ The specification is objected to by the Examiner	·,					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the o	Irawing(s) be held in abeyance. See	37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list of 	have been received. have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No d in this National	Stage			
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08)	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa	te				
Paper No(s)/Mail Date	o) 🗀 Other					

Election/Restrictions

A restriction requirement was sent out 11/12/08. Applicants replied to the requirement and amended and added new claims on 1/12/09. Due to the applicants amendments and addition of new claims, a new restriction requirement appears below. In particular, new claims 12-14 recite specific patient populations and new claim 15 recites various sequences. Since this is a new restriction requirement applicant may elect the same group/species as identified on 1/12/09 or may elect a new group/species. It is noted that this requirement requires the election of a specific patient population and identification sequence if group 1 is elected.

Claims 1-15 are under consideration.

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group 1, claim(s) 1-9,11-15 methods of administering MSH analogues.

Group 2, claim(s) 10, drawn to methods of manufacture.

The inventions listed as Groups 1-2 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: PCT Rule 13.2 defines "special technical features" as "those technical features that define a contribution which each of the claimed inventions,

Application/Control Number: 10/595,971 Page 3

Art Unit: 1654

considered as a whole, makes over the prior art." Claim 10 is drawn to a method of manufacture. Hruby et al (WO 87/04623 as cited in IDS 8/29/06) teach (page 7,9) methods of making alpha-MSH analogs as recited in claim 10. Thus the technical features are not a contribution over the prior art and the claims lack unity.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Election of Species

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

If group 1 is elected, species election is necessary for each of:

- 1. **alpha-MSH analogue**: a specific alpha-MSH analogue should be identified from those recited generically in claim 1. Applicant should uniquely identify the compound such that all variable groups are uniquely defined.
- 2. **Patient population**: a specific patient population should be identified from those recited in claims 12-14. Applicant should specify the allele/s (see claims 12-13) and/or skin type (see claim 14) of the patient population.
- 3. **Identification sequence**: a specific sequence and/or sequences should be identified from those in claim 15.

If group 2 is elected, species election is necessary for each of:

1. **alpha-MSH analogue**: a specific alpha-MSH analogue should be identified from those recited generically in claim 10. Applicant should uniquely identify the compound such that all variable groups are uniquely defined.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The claims are deemed to correspond to the species listed above in the following manner:

All claims are generic to at least one of the species.

There is an examination and search burden for the species due to their mutually exclusive characteristics. Each of the species are structurally distinct and one of skill in the art would not recognize that every alternative would behave in the same way. The species require a different field of search (e.g., searching different classes/subclasses or electronic resources, or employing different search queries); and/or the prior art applicable to one species would not likely be applicable to another species.

The election of the species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the election of species requirement, the election shall be treated as

Art Unit: 1654

an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected species.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the species unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other species.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to RONALD T. NIEBAUER whose telephone number is (571)270-3059. The examiner can normally be reached on Monday-Thursday, 7:30am-5:00pm, alt. Friday, EST.

Application/Control Number: 10/595,971 Page 6

Art Unit: 1654

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on 571-272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Anish Gupta/ Primary Examiner, Art Unit 1654

/Ronald T Niebauer/ Examiner, Art Unit 1654